Studies underscore advances in screening, mental health, health equity, and early intervention in diabetes care.New study examines benefits of continuous glucose monitoring (CGM) in people with type 2 diabetes (T2D) using glucagon-like peptide-1 ( GLP-1 ) therapy.Company strengthens leadership in type 1 diabetes (T1D) and T2D research, with more than 100 publications since 2020.BOSTON, June 11, 2025 /PRNewswire/ -- T1D Exchange, a nonprofit organization that drives meaningful research and improvement in care and outcomes in type 1 diabetes (T1D) and type 2 diabetes (T2D), today announced that new research using real-world data from its Quality Improvement Collaborative (T1DX-QI) and online patient Registry will be shared during 13 presentations at the American Diabetes Association (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois.The studies highlight emerging trends and outcomes in diabetes care, including efforts to improve screening for T1D autoantibodies, technology usage, particularly CGMs, and the increased use of GLP-1 therapies by individuals with T2D. Drawing on data from the organization's Registry of more than 20,000 people with T1D, several presentations offer insights into clinical outcomes as well as the broader impact of the disease, including financial strain, mental health challenges, and comorbid conditions. A full list of abstracts being presented is available here ."We are excited to unveil impactful research driven by our growing T1DX-QI network and robust patient Registry," said David Walton, Chief Executive Officer of T1D Exchange. "By uniting over 60 endocrinology clinics, data from 150,000+ individuals with T1D and T2D, and patient-reported outcomes from people with T1D and their caregivers, we're building a collaborative, evidence-driven knowledge base to expand our capabilities, deepen datasets, and generate insights that improve care for people with diabetes."Key studies include an oral presentation exploring equitable strategies to increase CGM adoption by people with T2D, expanding on prior research in T1D:276-OR, T1D Exchange Multicenter Study—Increasing CGM Adoption in Type 2 Diabetes on Sunday, June 22 , 3:15 - 4:15 p.m. CT in Room W185 A-DAdditionally, data from 12 studies will be presented during the General Poster Sessions on Saturday, June 21, Sunday, June 22, and Monday, June 23, from 12:30 - 1:30 p.m. CT in Poster Hall F1."Many of our presentations this year highlight the strength of our engaged T1D community and the value of our growing Registry

- Company invited to speak during three symposia on the impact of quality improvement, the cost of disparities in diabetes care, and addressing racial inequities – showcasing leadership in real-world diabetes data, equity, and practical implementation.- Company announces the new diabetes equity-focused ADEPT Conference, "Achieving Diabetes Equity in Practice Today," in collaboration with American Diabetes Association.BOSTON, June 17, 2024 /PRNewswire/ -- T1D Exchange, a nonprofit organization that drives meaningful research and improvement in care and outcomes in type 1 and type 2 diabetes, today announced that new research using real-world data from its Quality Improvement Collaborative (T1DX-QI) and online patient Registry will be shared in nine oral and 12 poster presentations during the 84th Scientific Sessions being held June 21-24, 2024, in Orlando, Florida.The studies detail trends and outcomes in the management of diabetes, including the importance of collaboration to close gaps and improve outcomes, the off-label use of glucagon-like peptide-1 (GLP-1) in people with type 1 diabetes (T1D), and varying characteristics and symptoms among users of continuous glucose monitors (CGMs). For a second consecutive year, T1D Exchange was selected for an ADA Presidents' Select Abstract, and this year the oral presentation is titled "Dynamics of Treatment Regimens and Glycemic Outcomes in >100,000 Children from International Pediatrics Diabetes Registries." A full list of abstracts can be found here."We're thrilled to share compelling research utilizing data from our core programs, the Quality Improvement Collaborative and patient Registry, both of which continue to grow," said David Walton, Chief Executive Officer of T1D Exchange. "Our expanded research capabilities and comprehensive patient data can generate novel insights to help partners improve products and care delivery."Oral Presentations & SymposiaADA Scholars Session: Does Quality Improvement Impact Outcomes for People Living with Diabetes?Examining New-Onset Type 1 Diabetes Educational Practices among Centers in the T1D Exchange Quality Improvement Collaborative (T1DX-QI)Longitudinal Assessment of Glycemia and Severe Hypoglycemia Among Adults with T1D: An Online SurveyHealth-related Quality of Life and Burden of Type 1 Diabetes and Severe Hypoglycemia in Adult Continuous Glucose Monitor UsersAssociation of Type 1 Diabetes Duration or Duration of Advanced Technology Utilization with Severe Hypoglycemic Event FrequencyUnderstanding Patterns of GLP-1/GLP-1 RA Use Among Individuals with Type 1 Diabetes: A T1D Exchange (T1DX) Online Registry AnalysisADA Presidents' Select Abstract: Dynamics of Treatment Regimens and Glycemic Outcomes in >100,000 Children from International Pediatrics Diabetes RegistriesImproving Diabetes Outcomes and Reducing Inequities through Collaboration: Perspective from the T1D ExchangeCurrent Approaches to Addressing Racial Equity—Insights from the T1D Exchange QI CollaborativeAdditionally, data from 12 studies will be presented during the General Poster Sessions on Saturday, June 22, and Sunday, June 23, at 12:30 - 1:30 p.m. ET in the Poster Hall West Hall A4-B2."The T1DX-QI network of over 60 diabetes centers cares for over 160,000 people living with type 1 and type 2 diabetes across the country," said Osagie Ebekozien, MD, MPH, Executive Vice President, Chief Medical Officer at T1D Exchange. "Our data and collaborative work highlight the importance of ongoing partnerships with diabetes centers to improve outcomes, advance new treatments, and close equity gaps.""With a direct connection to more than 20,000 people living with T1D, we've continued to expand our cohort and dataset to capture the daily experiences and challenges of individuals living with diabetes," said Wendy Wolf, PhD, Vice President of Registry and Outcomes Research at T1D Exchange. "Our research capabilities continue to expand as well, and we're now harnessing the power of patient-reported outcomes data linked with real-world CGM data of 3,500 individuals – enabling us to provide organizations with key data and insights to improve therapies for people living with T1D."ADEPT Health Equity ConferenceThe T1DX-QI has identified practical, evidence-based solutions to address diabetes health equity